LON:SALV SalvaRx Group Share Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding SalvaRx Group Plc Please log in to your account or sign up in order to add this asset to your watchlist. Add Compare Share Today's Range N/A50-Day Range 4.50▼ 4.5052-Week Range N/AVolume50,758 shsAverage Volume50,758 shsMarket Capitalization£1.65 millionP/E Ratio0.03Dividend YieldN/APrice TargetN/A ProfileChartCompetitorsHeadlines Receive SALV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SalvaRx Group and its competitors with MarketBeat's FREE daily newsletter. Email Address SALV Stock Forecast (MarketRank)Overall MarketRank™1.21 out of 5 starsAnalyst Opinion: 0.0Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 - 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for SalvaRx Group. Previous Next 4.8 Community Rank Outperform VotesSalvaRx Group has received 140 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSalvaRx Group has received 56 “underperform” votes. (Add your “underperform” vote.)Community SentimentSalvaRx Group has received 71.43% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about SalvaRx Group and other stocks. Vote “Outperform” if you believe SALV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SALV will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSalvaRx Group does not currently pay a dividend.Dividend GrowthSalvaRx Group does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SalvaRx Group insiders have not sold or bought any company stock. Previous Next 1.3 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of SalvaRx Group is 0.03, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.06.Price to Earnings Ratio vs. SectorThe P/E ratio of SalvaRx Group is 0.03, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.25. Previous Next See Top Rated MarketRank™ Stocks Here About SalvaRx GroupSalvaRx Group plc discovers and develops immune-oncology drugs. The company is based in Ramsey, Isle of Man.Read More SALV Stock News HeadlinesApril 30, 2020 | finance.yahoo.comWho Are The Major Shareholders In SalvaRx Group plc (LON:SALV)?April 30, 2020 | finance.yahoo.comSalvaRx Group plc (LON:SALV): Are Analysts Optimistic?April 30, 2020 | finance.yahoo.comWho Are SalvaRx Group plc’s (LON:SALV) Major Shareholders?February 18, 2020 | www.lse.co.ukSalvarx Group Plc Share ChatFebruary 14, 2020 | www.bloomberg.comAnanda Developments Plc: Proposed Acquisition of Tiamat AgricultureJanuary 9, 2020 | www.lse.co.ukSalvaRx Shares To Be Cancelled On London Stock ExchangeSeptember 26, 2019 | www.morningstar.co.ukSalvaRx Turns To Interim Profit, Evaluating Takeover OpportunitiesJuly 26, 2019 | markets.businessinsider.comPortage Announces Filing of Application for Management Cease Trade OrderJuly 21, 2019 | www.lse.co.ukSalvarx Group Plc Share Chat (SALV)July 9, 2019 | www.morningstar.co.ukSalvaRx Sees Shares Suspended Following Failure To Complete DealJune 28, 2019 | www.morningstar.co.ukSalvaRX Loss Widens, Mulling Options Ahead Of Cash Shell AIM DeadlineMay 6, 2019 | finance.yahoo.comPortage Announces Change of CEOJanuary 8, 2019 | finance.yahoo.comShareholders approve Acquisition of SalvaRx LimitedSee More Headlines Industry, Sector and Symbol Stock ExchangeLON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:SALV Previous SymbolLON:3LEG CUSIPN/A CIKN/A Webwww.salvarx.io Phone+44-1624-811611FaxN/AEmployees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio0.03 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio14.50 Current Ratio1.89 Quick Ratio1.89 Sales & Book Value Annual Sales£64.50 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow3.50 Book ValueGBX 15.40 per share Price / BookN/AMiscellaneous Outstanding Shares36,700,000Free FloatN/AMarket Cap£1.65 million OptionableNot Optionable BetaN/A SalvaRx Group Frequently Asked Questions Who are SalvaRx Group's key executives? SalvaRx Group's management team includes the following people: Mr. Denham Hervey Newall Eke, CFO & Director (Age 67) Who are some of SalvaRx Group's key competitors? Some companies that are related to SalvaRx Group include Innovotech (IOT), Therapix Biosciences (TRPXY), Revive Therapeutics (RVV), Roquefort Therapeutics (ROQ), Biopharmx (BPMX), Naturally Splendid Enterprises (NSP), Cizzle Biotechnology (CIZ), Motif Bio (MTFB), Pascal Biosciences (PAS), Physiomics (PYC), Nuformix (NFX), Kaleido Biosciences (KLDO), Hemispherx BioPharma (HEB), Pacgen Life Science Co. (PBS.V) (PBS) and Medifocus Inc. (MFS.V) (MFS). View all of SALV's competitors. What other stocks do shareholders of SalvaRx Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other SalvaRx Group investors own include Premier African Minerals (PREM), Cradle Arc (CRA), Cora Gold (CORA), Big Sofa Technologies Group (BST), Bahamas Petroleum (BPC), Bacanora Lithium (BCN), AutoZone (AZO), Angus Energy (ANGS), Allergy Therapeutics (AGY) and AFR.L (AFR). What is SalvaRx Group's stock symbol? SalvaRx Group trades on the London Stock Exchange (LON) under the ticker symbol "SALV." How do I buy shares of SalvaRx Group? Shares of SALV and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. How much money does SalvaRx Group make? SalvaRx Group (LON:SALV) has a market capitalization of £0.00 and generates £64.50 million in revenue each year. How many employees does SalvaRx Group have? SalvaRx Group employs 2 workers across the globe. How can I contact SalvaRx Group? SalvaRx Group's mailing address is Commerce House, 1 Bowring Road, RAMSEY, RAMSAY, IM8 2LQ, Isle of Man. The official website for SalvaRx Group is www.salvarx.io. The company can be reached via phone at +44-1624-811611. This page (LON:SALV) was last updated on 6/30/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
